An integrative genomic and proteomic analysis in breast cancer patients negative and positive to 18F-FDG PET screening.

Metabolic signature of breast cancer patients negative and positive to 18F-FDG PET screening.

Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria

BACKGROUND: In this paper the clinical value of PET for early prediction of tumor response to erlotinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen is evaluated. The aim was to compare the early metabolic treatment response using European Organization for Research and Treatment of Cancer (EORTC) 1999 recommendations and PET Response Criteria in Solid Tumors (PERCIST), and the standard treatment response using Response Evaluation Criteria in Solid Tumors (RECIST). METHODS: Twenty patients with stage IV NSCLCwere enrolled prospectively. PET/CT studies were performed before, then 48 hours, and 45 days after…